This study is for people with relapsed or refractory multiple myeloma (RRMM). Multiple myeloma is a type of cancer that affects white blood cells in the bone marrow. "Relapsed" means the cancer has returned after treatment, and "refractory" means it did not respond to previous treatment. The study compares two different treatments to see which is better.

Participants must have been diagnosed with multiple myeloma, have measurable disease, and have received 1 or 2 previous treatments. They need to have a performance status score of 0, 1, or 2, which means they should be able to carry out daily activities.

• Study Duration: The study lasts until the disease progresses, side effects become too severe, or a participant chooses to stop.
• Study Visits: Participants will have regular visits to monitor their health and progress with the treatment.
• Age Requirement: Participants should be adults with documented multiple myeloma.

Before joining, participants will be screened to ensure they meet all criteria and do not have conditions that might affect the study results.